Emerging Business Models in the Pharmaceutical Industries ...

1%
2%
2%
2%
3%
23%
4%
5%
Aventis Revenues by Geography
(in Percentage)
6%
13%
Source: Company’s Annual Reports
39%
USA
France
Germany
Japan
Italy
UK
Canada
Spain
Mexico
Brazil
Other countries
Aventis
Strategic Direction
The core strategy of Aventis is to create value by rapidly
developing, launching and marketing innovative pharmaceuticals
that satisfy unmet medical needs in large patient populations.
Aventis is aggressively deploying a targeted in-licensing and
alliance strategy to supplement organic growth and enhance its
R&D efforts with high value and late stage products. The
company is also trying to focus on maximising the value of
existing and recently launched global brands through commercial
investments.
Aventis has more than 300 collaborations in pre-clinical
research, development and technology projects with academic
and scientific institutions, biotechnology and other
pharmaceutical companies. The company is also pursuing
targeted acquisitions in strategic areas to fill technological gaps.
In July 2003, Aventis and ImmunoGen signed a collaboration
agreement to discover, develop, and commercialise novel
antibody-based anti-cancer products. In the field of genomics the
company has partnered with Procode for cardiovascular
functional genomics and with Incyte Pharmaceuticals, Ingenuity
and Celera for genomic information.
It has a research collaboration on oncology targets with Avalon
Pharmaceuticals of Maryland, U.S., and a global agreement
(excluding Japan) under which the companies will jointly develop
and commercialise Vascular Endothelial Growth Factor (VEGF)
Trap, Regeneron lead anti-angiogenesis compound.
Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 65